Ginkgo Bioworks announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery. Ginkgo has acquired Reverie’s infrastructure and software for training large-scale AI foundation models and four of Reverie’s key AI team members will join Ginkgo. The acquisition is intended to strengthen Ginkgo’s AI/ML-driven discovery services offering and to accelerate Ginkgo’s work to build next-generation biological foundation models.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers
- Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers
- Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs
- Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions
- Cathie Wood’s ARK Investment bought 2.46M shares of Ginkgo Bioworks today